Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, announced that Swissmedic has accepted the marketing authorization application (MAA) for BRUKINSA, a treatment option for adult patients wi...
BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA ® (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 month...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA ® (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 mon...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, today announced that it will host an investor conference call and webcast ...
BeiGene (NASDAQ:BGNE): Q2 GAAP EPADS of -$5.23 misses by $0.82. Revenue of $149.99M (+128.5% Y/Y) misses by $24.88M. Shares -1.75% AH. Press Release For further details see: BeiGene EPS misses by $0.82, misses on revenue
Recorded product revenue of $138.6 million for the second quarter, representing a 111% increase from $65.6 million in the prior year period; additional approvals of five new indications and two new products in China Reported positive interim Phase 3 BRUKINSA data from two gl...
China's recent capital market crackdown seems arbitrary but consistent. The Party's actions need to be viewed through the lens of geopolitics, domestic control, and culture. Investors need to pay heed to government's nationalistic agenda. For further details see: Chinese...
BeiGene (NASDAQ:BGNE) announces its plans to build a new campus for R&D and manufacturing at the Princeton West Innovation Campus in Hopewell, New Jersey. The company has entered into a purchase agreement to acquire an ~42-acre site with over one million square feet of developab...
Company expects to recruit hundreds of new hires in the area to support clinical research, development, regulatory, pharmacovigilance, and manufacturing BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innova...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...